Skip to main content
. 2022 Dec 6;8(2):e002650. doi: 10.1136/rmdopen-2022-002650

Figure 4.

Figure 4

Patients with AIRD under rituximab (RTX) therapy (n=40). r and p according to Spearman’s rank correlation between days from last RTX infusion to first vaccination and neutralising capacity after second COVID-19 vaccination. Dotted line marks the cut-off value for positivity following manufacturer’s protocol (≥30%).